PSMD1 and common variable immunodeficiency: Interestingly, most CVID patients receiving subcutaneous immunoglobulin replacement therapy (81%) had detectable levels of anti-S1 antibodies, while only three out of seven (43%) patients receiving intravenous immunoglobulin replacement therapy were anti-S1 IgG positive (Supplementary Figure 1).